AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02271568 — intervention group
Intervention type: OTHER
Intervention: Intensive medical therapy
Description: intensive medical therapy according to published guidelines by ADA and EASD
Study NCT04375371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Obese patients who haveundergone bariatric surgery as part of routine clinical management within the indication of this intervention.
Study NCT05723978 — intervention group
Intervention type: PROCEDURE
Intervention: Selective extended dissection of pancreaticoduodenectomy
Description: An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
Study NCT02554500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
Study NCT01523262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preconditioning
Description: peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
Study NCT01523262 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal surgery, with sham intervention without inflating arm cuff
Study NCT03953196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imvanex
Description: Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
Study NCT03953196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
Study NCT03953196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
Study NCT03953196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candin
Description: Candin 0.1 mL solution for injection will be administered as one intradermal injection.
Study NCT03953196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: 3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
Study NCT03953196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Control
Description: Saline control solution for injection will be administered as one intradermal injection.
Study NCT02900196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 - Fermented dairy drink
Description: 1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
Study NCT02900196 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2 - Acidified dairy drink
Description: 2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
Study NCT03591991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.
Study NCT03591991 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg placebo . After admission, patients were treated with 10 mg placebo once daily for 3 mouths.
Study NCT03355716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: Bupivacaine 25 ml (0.25%)
Study NCT03355716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Bupivacaine 25 ml (0.25%)
Study NCT03355716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Morphine (3.0 mg)
Study NCT03355716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl (30.0 Mc)
Study NCT03355716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine:
Description: ketamine (0.5 mg/kg).
Study NCT03155568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: sciatic nerve block at popliteal fossa
Study NCT03155568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ankle block
Description: block of major nerves supplying the foot at the level of the ankle
Study NCT03155568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
Study NCT02276001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Study NCT02276001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Study NCT02023606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810M
Study NCT04152278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila
Description: three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)
Study NCT00901316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine Measures Group
Description: Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures.
Study NCT00901316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bleach Bath Group (Bleach plus routine measures)
Description: Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths.
Study NCT00615511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo pregnenolone
Description: Sugar pill, taken twice a day
Study NCT00615511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pregnenolone
Description: 500mg in tablet form taken orally twice a day
Study NCT02197130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
Study NCT02197130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
Study NCT02197130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
Study NCT01594762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical pexiganan cream 0.8%
Description: 14 days of treatment
Study NCT01594762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo cream
Description: 14 days of treatment
Study NCT01594762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard wound care
Description: 14 days of treatment
Study NCT01594762 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard wound care
Description: 14 days of treatment
Study NCT02320669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triostat
Description: Bolus of Triiodothyronine followed by infusion for 48 hours
Study NCT02320669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bolus of Placebo followed by infusion for 48 hours
Study NCT02151383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Serelaxin was administered intravenously for up to 48 hours.
Study NCT00172133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11 (drug)
Description: 100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
Study NCT03915821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECT
Description: Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,
Study NCT03105791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formal education regarding opioid usage
Description: Participannts watched a 2 minute video and were given educational materials
Study NCT02854553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectus sheath block
Description: ultrasound guided rectus sheath block
Study NCT04162535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~* Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~* Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~* Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop
Study NCT04162535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood extraction
Description: The patients will donate after consent 10 ml of blood prior and after surgery for further study
Study NCT04162535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
Study NCT04162535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients will receive a general anesthesia with Propofol as anesthetic agent
Study NCT03219567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: Optical coherence tomography (OCT) is a non-contact, micrometer scale imaging technique, it provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D.~The study team will develop the hardware systems and software algorithms necessary to enable simultaneous OCT imaging of all the refractive surfaces of the eye.
Study NCT03219567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in the body.
Study NCT04390568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimap
Description: Spesolimap
Study NCT02448004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
Study NCT00880763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
Study NCT00880763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon (peg-IFN)
Description: Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
Study NCT01649271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 3-weekly
Study NCT01649271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: at MTD level
Study NCT01649271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 3-weekly
Study NCT01649271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: weekly
Study NCT01649271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: escalating dose
Study NCT00880763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (peg-IFN)
Description: Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
Study NCT00880763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
Study NCT00880763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
Study NCT00444925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine tartrate
Description: 4 mg once daily (OD) for 12 weeks
Study NCT00880763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to vaniprevir oral capsule twice daily for 28 days
Study NCT03695861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body 18F-FDG PET-CT scan
Description: A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
Study NCT04427644 — intervention group
Intervention type: PROCEDURE
Intervention: Laparascopic Sleeve Gastrectomy
Description: Operations performed for complciation of laparascopic sleeve gastrectomy
Study NCT04427644 — intervention group
Intervention type: PROCEDURE
Intervention: İnterventional radiologic drainage
Description: İnterventional radiologic drainage of gastric leakage
Study NCT02186990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 2,5 mg/kg
Study NCT02186990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate
Description: 0,3 mg/kg
Study NCT02186990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate-propofol
Description: 0,15 mg/kg etomidate + 1,25 mg/kg propofol
Study NCT04427644 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complte Blood Count and Biochemical evaluation
Description: blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
Study NCT00307242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil
Study NCT01792245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Study NCT04427644 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography
Description: Admitted to observe leakage
Study NCT03009812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Longitudinal uterine incision
Study NCT03009812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse uterine incision
Study NCT03475901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality App
Description: Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
Study NCT02560532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Concentrated solution for intravenous injection
Study NCT00003997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irofulven
Study NCT03884491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine IV
Description: an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
Study NCT05126940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
Description: Patients were placed in a semi-recumbent or supine position depending on their respiratory tolerance. For each side of the chest, 4 zones have to be assessed : 2 anterior and 2 lateral. The operator should calculate the number of B-lines when present .
Study NCT00166036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 12 Weeks of Oral Atorvastatin 10 mg therapy.
Study NCT00166036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 12 Weeks of Oral Pravastatin 80 mg therapy.
Study NCT00752830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328
Description: Oral capsule, single dose
Study NCT04064619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate 5 MG
Description: gradual weaning of drug vs. stopping
Study NCT04064619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 5 MG
Description: gradual weaning of drug vs. stopping
Study NCT02771795 — intervention group
Intervention type: DRUG
Intervention: Herceptin (trastuzumab)
Description: Intravenous administration
Study NCT02771795 — intervention group
Intervention type: DRUG
Intervention: SB3 (proposed trastuzumab biosimilar)
Description: Intravenous administration
Study NCT04650503 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00599898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
Study NCT00599898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
Study NCT00713999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with anti-STI and anti-schistosoma regimens
Description: Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
Study NCT01302613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
Study NCT01302613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.